---
title: "After 2026-01-30, Bender Jeremy's DAWN filings point to a sequence worth tracking"
type: news
slug: bender-jeremy-dawn-5-2m-career-insider-sales
canonical_url: https://13finsight.com/news/bender-jeremy-dawn-5-2m-career-insider-sales
published_at: 2026-03-02T17:52:18.603Z
updated_at: 2026-03-05T17:03:22.499Z
author: Alex Rivera
author_title: Breaking News Editor
author_url: https://13finsight.com/authors/alex-rivera
word_count: 86
locale: en
source: 13F Insight
---

# After 2026-01-30, Bender Jeremy's DAWN filings point to a sequence worth tracking

> Bender Jeremy's DAWN insider record stands at $5.2M cumulative sales (latest filing 2026-01-30); focus on sequence, transaction-code mix, and ownership trend over time.

Bender Jeremy continues to shape the insider narrative for DAWN. Cumulative sales are $5.2M, but the higher-value insight is in how filings cluster around 2026-01-30 and after. Recent Form 4 Prints DateCodeSharesPriceEst. Value 2026-01-30A237,000N/AN/A 2026-01-30A355,000$11.16$4.0M 2025-11-25G7,225N/AN/A 2025-11-25G7,225N/AN/A 2025-11-25G300,000N/AN/A 2025-11-25G300,000N/AN/A 2025-11-25G300,000N/AN/A 2025-11-25G300,000N/AN/A Context for Day One Biopharmaceuticals, Inc. In headline-sensitive environments, insider prints are easy to overread. A disciplined approach is to watch persistence outside expected liquidity windows. Search-Based Context Current search results for industry context Bottom Line Informative signal, not yet decisive; wait for follow-through data.

---

Source: 13F Insight — https://13finsight.com/news/bender-jeremy-dawn-5-2m-career-insider-sales
Author: Alex Rivera — https://13finsight.com/authors/alex-rivera
Last updated: 2026-03-05T17:03:22.499Z